Paulo Fontoura
Paulo Fontoura
Global Head of Neuroscience, Roche Pharmaceuticals
Email verificata su
Citata da
Citata da
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New England Journal of Medicine 376 (3), 209-220, 2017
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
The parkinson progression marker initiative (PPMI)
K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ...
Progress in neurobiology 95 (4), 629-635, 2011
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
M Platten, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, ...
Science 310 (5749), 850-855, 2005
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
NA Naryshkin, M Weetall, A Dakka, J Narasimhan, X Zhao, Z Feng, ...
Science 345 (6197), 688-693, 2014
The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ...
European Journal of Neurology 18 (1), 69-77, 2011
Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammation
A Chora, P Fontoura, A Cunha, TF Pais, S Cardoso, PP Ho, LY Lee, ...
The Journal of clinical investigation 117 (2), 438-447, 2007
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis
WH Robinson, P Fontoura, BJ Lee, HEN De Vegvar, J Tom, R Pedotti, ...
Nature biotechnology 21 (9), 1033-1039, 2003
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review
A Langer-Gould, RA Popat, SM Huang, K Cobb, P Fontoura, MK Gould, ...
Archives of neurology 63 (12), 1686-1691, 2006
Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway
H Garren, PJ Ruiz, TA Watkins, P Fontoura, LVT Nguyen, ER Estline, ...
Immunity 15 (1), 15-22, 2001
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
S Ostrowitzki, RA Lasser, E Dorflinger, P Scheltens, F Barkhof, ...
Alzheimer's research & therapy 9 (1), 1-15, 2017
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination
R Pedotti, JJ DeVoss, S Youssef, D Mitchell, J Wedemeyer, R Madanat, ...
Proceedings of the National Academy of Sciences 100 (4), 1867-1872, 2003
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects
C Sievers, M Meira, F Hoffmann, P Fontoura, L Kappos, RLP Lindberg
Clinical immunology 144 (1), 70-79, 2012
An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems
PP Ho, P Fontoura, PJ Ruiz, L Steinman, H Garren
The Journal of Immunology 171 (9), 4920-4926, 2003
Drug discovery for autism spectrum disorder: challenges and opportunities
A Ghosh, A Michalon, L Lindemann, P Fontoura, L Santarelli
Nature reviews Drug discovery 12 (10), 777-790, 2013
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
E Bertini, E Dessaud, E Mercuri, F Muntoni, J Kirschner, C Reid, ...
The Lancet Neurology 16 (7), 513-522, 2017
Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial
JA Quiroz, P Tamburri, D Deptula, L Banken, U Beyer, M Rabbia, ...
JAMA psychiatry 73 (7), 675-684, 2016
Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis
P Fontoura, PP Ho, J DeVoss, B Zheng, BJ Lee, BA Kidd, H Garren, ...
The Journal of Immunology 173 (11), 6981-6992, 2004
Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results
EA Youssef, E Berry-Kravis, C Czech, RJ Hagerman, D Hessl, CY Wong, ...
Neuropsychopharmacology 43 (3), 503-512, 2018
A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease
PP Ho, P Fontoura, M Platten, RA Sobel, JJ DeVoss, LY Lee, BA Kidd, ...
The Journal of Immunology 175 (9), 6226-6234, 2005
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20